



Fortis Healthcare Limited
Support Office:
Tower A, Unitech Business Park,
Block - F, South City 1, Sector - 41,
Gurgaon, Haryana - 122001 (India)
Tel : 0124 492 1021
Fax : 0124 492 1041
Ambulance : 105010
E-mail : secretarial@fortishealthcare.com
Website : www.fortishealthcare.com

FHL/SEC/STEX/RR/2016-17

August 4, 2016

**The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051
Scrip Symbol: FORTIS**

**BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
Scrip Code:532843**

Sub: Outcome of the Board Meeting

Dear Sir

This is to inform you that the Board of Directors of the Company at their meeting held today i.e. August 4, 2016, *inter-alia*, considered and approved the following:

1. Un- audited Financial Results and Limited Review Report of the Company for the quarter ended on June 30, 2016.
2. Re-appointment of Mr. Sunil Godhwani and Mr. Ravi Umesh Mehrotra, Directors of the Company, who are liable to retire by rotation at the ensuing Annual General Meeting and being eligible offers themselves for re-appointment.
3. Convening of 20th Annual General Meeting of the Company on Tuesday, September 27, 2016 at 12.00 Noon at PHD Chamber of Commerce and Industry, 4/2 Siri Institutional Area, August Kranti Marg, New Delhi – 110 016.
4. Closure of Register of Members and Share Transfer Books of the Company from Tuesday, September 20, 2016 to Tuesday, September 27, 2016 (both days inclusive) for the purpose of Annual General Meeting. The cut-off date for reckoning members eligible for voting shall be September 20, 2016.
5. Shifting of Registered office from NCT of Delhi to State of Punjab and Notice of Postal Ballot along with Appointment of scrutinizer for the same.



FORTIS HEALTHCARE LIMITED

Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025 (India)
Tel: +91-11-2682 5000, Fax: +91-11-4162 8435, CIN: L85110DL1996PLC076704



Fortis Healthcare Limited

Support Office:

Tower A, Unitech Business Park,
Block - F, South City 1, Sector - 41,
Gurgaon, Haryana - 122001 (India)

Tel : 0124 492 1021

Fax : 0124 492 1041

Ambulance : 105010

E-mail : secretarial@fortishealthcare.com

Website : www.fortishealthcare.com

6. enabling fund raising option upto Rs 5000 Crore including but not limited to qualified institutions placement (QIP), Foreign Currency Convertible Bond (FCCB), convertible securities or any other method and to recommend the same to the shareholders for their approval at the ensuing Annual General Meeting of the Company.
7. In-principle approval to demerge its diagnostic business which includes operations in SRL Limited, and in this regard the Board has formed a Restructuring Committee to detail the nuances of the demerger structure, including valuation, share entitlement ratio and other incidental matters and to present the same before the Board on August 19, 2016 for final approval.

Copy of the Un-audited Financial Results, Limited Review Report and press release being issued in this regard is attached for your reference and records.

This is for your information and records please. The meeting concluded at 4:15 p.m.

Yours faithfully

For Fortis Healthcare Limited

Rahul Ranjan
Company Secretary



FORTIS HEALTHCARE LIMITED

Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025 (India)

Tel: +91-11-2682 5000, Fax: +91-11-4162 8435, CIN: L85110DL1996PLC076704

Deloitte Haskins & Sells LLP

Chartered Accountants
Deloitte Centre
Anchorage II
100/2 Richmond Road
Bengaluru - 560 025
India

Tel: +91 (080) 6627 6000
Fax: +91 (080) 6627 6013

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
FORTIS HEALTHCARE LIMITED

1. We have reviewed the Standalone Unaudited Financial Results ("Results") of FORTIS HEALTHCARE LIMITED ("the Company") for the quarter ended 30 June, 2016 included in the accompanying Statement of Unaudited Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These Results included in the Statement, which are the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Results included in the Statement based on our review.
2. We conducted our review of the Results included in the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Results included in the Statement are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Results included in the Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We have not reviewed the Results for the quarter ended June 30, 2015 included in the Statement which have been presented solely based on the financial information compiled by the Management.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



V. SRIKUMAR
Partner

(Membership No. 84494)

Bangalore, 4 August, 2016
VS/RT/2016

**INDEPENDENT AUDITORS' REVIEW REPORT ON
REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
FORTIS HEALTHCARE LIMITED**

1. We have reviewed the Consolidated Unaudited Financial Results ("Consolidated Results") of **FORTIS HEALTHCARE LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its share of the profit/(loss) of its associates and joint ventures for the quarter ended 30 June, 2016 included in the accompanying Statement of Unaudited Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These Consolidated Results included in the Statement, which are the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Consolidated Results included in the Statement based on our review.
2. We conducted our review of the Consolidated Results included in the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Results included in the Statement are free of material misstatement. A review is limited primarily to inquiries of the Holding Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following entities
 - a. Fortis Healthcare Limited (the Holding Company)
 - b. Fortis Hospitals Limited ("FHsL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and joint ventures:
 - i. Birdie & Birdie Realtors Private Limited (wholly owned subsidiary of FHsL)
 - ii. Fortis C-Doc Healthcare Limited (joint venture of FHsL)
 - iii. Fortis Health Management (East) Limited (subsidiary of FHsL)
 - iv. Fortis Cancer Care Limited ("FCCL") (wholly owned subsidiary of FHsL) and the results of its subsidiary Lalitha Healthcare Private Limited
 - v. Fortis Cauvery (joint venture of FCCL)
 - vi. Fortis Malar Hospitals Limited (subsidiary of FHsL) and the results of its wholly owned subsidiary Malar Stars Medicare Limited.
 - vii. Fortis Emergency Services Limited (subsidiary of FHsL)
 - viii. Stellant Capital Advisory Services Private Limited with effect from 03 November, 2015 (wholly owned subsidiary of FHsL) and the results of its wholly owned subsidiary Religare Health Trust Trustee Manager Pte Limited with effect from 01 February, 2016.

- c. Escorts Heart Institute and Research Centre Limited ("EHIRCL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and associate:
 - i. Fortis Health Staff Limited (subsidiary of EHIRCL)
 - ii. Fortis Asia Healthcare Pte. Limited (wholly owned subsidiary of EHIRCL) and the results of its wholly owned subsidiary Fortis Healthcare International Pte. Limited ("FHIPL")
 - iii. Radlink Asia Pte. Limited (wholly owned subsidiary of FHIPL) and the results of its subsidiaries and associates up to 12 May, 2015
 - iv. Fortis Healthcare Singapore Pte. Limited (wholly owned subsidiary of FHIPL) up to 05 April, 2015
 - v. Lanka Hospitals Corporation Plc (associate of FHIPL)
 - vi. Fortis Healthcare Middle East LLC (subsidiary of FHIPL)
 - vii. Mena Healthcare Investment Company Limited (subsidiary of FHIPL) and the results of its wholly owned subsidiary Medical Management Company Limited
 - viii. SRL Diagnostics FZ-LLC (wholly owned subsidiary of FHIPL)
 - d. SRL Limited ("SRL") (subsidiary of the Holding Company) and the results of its subsidiaries and joint ventures:
 - i. SRL Diagnostics Private Limited (wholly owned subsidiary of SRL)
 - ii. SRL Reach Limited (wholly owned subsidiary of SRL)
 - iii. DDRC SRL Diagnostics Services Private Limited (joint venture of SRL)
 - iv. Super Religare Reference Laboratories (Nepal) Private Limited (joint venture of SRL)
 - e. Hiranandani Healthcare Private Limited (subsidiary of the Holding Company)
 - f. Fortis Healthcare International Limited ("FHIL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and associate:
 - i. Fortis Global Healthcare (Mauritius) Limited (wholly owned subsidiary of FHIL)
 - ii. Fortis Medicare International Limited (associate of FHIL)
 - iii. Religare Health Trust and its subsidiaries (associates of FHIL)
 - iv. Medical and Surgical Centre Limited (associate of FHIL)
 - g. Fortis La Femme Limited (wholly owned subsidiary of the Holding Company)
4. The consolidated financial results includes the Group's share of profit after tax of Rs. 122 lacs and total comprehensive income of Rs. 122 lacs for the quarter ended June 30, 2016, as considered in the consolidated financial results, in respect of 1 Joint Venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our report on the Consolidated Results included in the Statement, in so far as it relates to the amounts and disclosures included in respect of the joint venture, is based solely on the report of the other auditor.

We did not review the interim financial results of 1 overseas joint venture whose interim financial results, prepared under Nepal Accounting Standard "NAS", reflect Group's share of profit after tax of Rs. 11 lacs and total comprehensive income of Rs. 11 lacs for the quarter ended June 30, 2016, as considered in the consolidated financial results and 3 overseas associates whose interim financial results, prepared under Singapore Financial Reporting Standards "SFRS", reflect Group's share of loss after tax of Rs. 1,115 lacs and total comprehensive loss of Rs. 1,394 lacs for the quarter ended June 30, 2016, as considered in the consolidated financial results. The interim financial results of the joint venture and associates have been prepared in accordance with NAS and SFRS respectively and have been reviewed by other auditors who have submitted their conclusions, prepared under generally accepted auditing standards of their respective countries. The Management of the Holding Company has converted these financial results of the joint venture and associates to accounting principles generally accepted in India (India Accounting Standard),

for the purpose of the preparation of the Holding Company's consolidated financial results under accounting principles generally accepted in India (India Accounting Standard). Our report on the Consolidated Results included in the Statement, thus in so far it relates to amounts and disclosures included in respect of the joint venture and associates, is based solely on the reports of other auditors and our review of the conversion process followed by the Management.

5. The consolidated financial results includes the interim financial results of 16 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 1,382 lacs for the quarter ended June 30, 2016, and total profit after tax of Rs. 482 lacs and total comprehensive loss of Rs. 2,153 lacs for the quarter ended 30 June, 2016, as considered in the consolidated financial results. The consolidated financial results also includes the Group's share of profit after tax of Rs. 397 lacs and total comprehensive income of Rs. 397 lacs for the quarter ended 30 June, 2016, as considered in the consolidated financial results, in respect of 3 associates and 2 joint ventures, based on their interim financial results which have not been reviewed by their auditors. These financial results have been prepared by the management, and our conclusion is based solely on the management certified accounts.
6. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred to in paragraph 4 above and except for the possible effects of the matter described in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Results included in Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We have not reviewed the consolidated financial results for the quarter ended June 30, 2015 which have been presented solely based on the financial information compiled by the Management.
8. We draw attention to notes 6(a), 6(b) and 6(c) to the Statement, regarding matters relating to income tax demands, termination of certain land leases allotted by Delhi development Authority (DDA), and non-compliance with order of the Honorable High court of Delhi in relation to provision of free treatment/beds to poor against one of the subsidiaries ("Escorts Heart Institute and Research Centre Limited"). Based on the advice given by external legal counsel, no provision/adjustment has been considered necessary by the Management in this regard in the Consolidated Results included in the Statement.

Our opinion on the Consolidated Results included in the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



V. SRIKUMAR
Partner
(Membership No. 84494)

Bangalore, 4 August, 2016
VS/RT/2016

FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

Particulars	(₹ In lacs)			
	Consolidated		Standalone	
	Quarter ended		Quarter ended	
	30-Jun-16 (Unaudited)	30-Jun-15 (Unaudited) (Refer note 2)	30-Jun-16 (Unaudited)	30-Jun-15 (Unaudited) (Refer note 2)
1. Income from operations	110,322	102,495	16,400	15,036
2. Other operating income	1,794	932	209	385
3. Total income from operations (1+2)	112,116	103,427	16,609	15,421
4. Expenses				
(a) Cost of material consumed	25,399	23,854	4,016	3,834
(b) Employee benefits expenses	22,425	20,187	4,830	4,333
(c) Hospital service fee	15,400	14,665	3,458	3,322
(d) Professional charges to doctors	12,848	10,793	2,007	1,967
(e) Net depreciation/ impairment & amortisation expenses	4,756	5,327	621	577
(f) Other expenses	29,781	29,082	4,438	5,918
Total expenses	110,609	103,908	19,370	19,951
5. Profit/ (loss) from operations before other income, finance costs and exceptional items (3-4)	1,507	(481)	(2,761)	(4,530)
6. Other income	3,299	3,986	4,675	4,190
7. Profit/ (loss) before finance costs and exceptional items (5+6)	4,806	3,505	1,914	(340)
8. Finance costs	4,199	3,415	2,619	1,591
9. Profit / (loss) from operations before exceptional items (7-8)	607	90	(705)	(1,931)
10. Exceptional gain (refer note 7)	-	8,725	-	-
11. Profit / (loss) from operations before tax (9+10) (including profit/loss) attributable to discontinued operations, refer note 8)	607	8,815	(705)	(1,931)
12. Tax expense	287	957	-	-
13. Net profit / (loss) after tax for the period before share in profit of associates and joint ventures (11-12)	320	7,858	(705)	(1,931)
14. Add : Share in profit of associate companies and joint ventures	2,206	1,882	-	-
15. Net profit / (loss) for the period (13+14)	2,526	9,740	(705)	(1,931)
Attributable to:				
Owners of the Company	1,618	9,315	(705)	(1,931)
Non Controlling interest	908	425	-	-
16. Other Comprehensive Income (including relating to associates and joint venture (after tax)) ('OCI')	(1,711)	(628)	-	96
17. Total comprehensive income (15+16)	815	9,112	(705)	(1,835)
Attributable to:				
Owners of the Company	(90)	8,690	(705)	(1,835)
Non Controlling interest	905	422	-	-
18. Paid-up equity share capital (Face Value ₹10 per Share)	46,320	46,288	46,320	46,288
19. Earnings per share				
- Basic	0.35	2.01	(0.15)	(0.42)
- Diluted	0.18	1.88	(0.15)	(0.42)
20. Earnings before depreciation and amortization expense, finance costs, exceptional items and tax expenses (EBITDA) (refer note 10)	9,562	8,832	2,535	237



FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

Notes to the results

1. The above financial results for the quarter ended June 30, 2016 have been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their respective meetings held on August 3, 2016 and August 4, 2016.
2. The financial results pertaining to the quarter ended 30 June, 2015 were subjected to limited review by another firm of chartered accountants under the Previous GAAP. The Management has exercised necessary due diligence for conversion of the financial results to Ind AS to ensure that the financial results provide a true and fair view of its affairs in accordance with the Ind AS.
3. The Company adopted Ind AS from April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The reconciliation between financial results for the quarter ended June 30, 2015, as previously reported (referred to as 'Previous GAAP') and Ind AS is as under:-

Sr. No.	Nature of Adjustment	(₹ in lacs)	
		Consolidated Quarter ended June 30, 2015	Standalone Quarter ended June 30, 2015
	Net profit before minority interest under Previous GAAP (A)	9,314	(1,670)
1	Borrowings & debt portion of compound instruments accounted based on effective interest rate	(131)	(78)
2	Financial assets accounted at fair value through profit and loss	960	(12)
3	Share based payments accounted based on fair value	(50)	(87)
4	Change in classification of associates/ subsidiaries	3	-
5	Deferred tax impact	(146)	-
6	Actuarial (gain)/ loss on employee defined benefit plans recognised through other comprehensive income (OCI)	(235)	(95)
7	Others	25	(6)
	Total adjustments (1+2+3+4+5+6+7) (B)	426	(261)
	Net profit before OCI as per Ind AS (C = A+B)	9,740	(1,931)
	Other Comprehensive Income (OCI) after tax (D)	(628)	96
	Total Comprehensive Income as per Ind AS (C+D)	9,112	(1,835)

4. Segment Reporting

Business segments:

The Group is primarily engaged in the business of healthcare services, which in the opinion of management is considered to be the only reportable business segment as per Indian Accounting Standard 108 on 'Operating Segments' issued by Ministry Of Corporate Affairs, Government of India as notified under section 133 of the Companies Act, 2013. Healthcare services include various patient care services delivered through clinical establishment, medical services companies, pathology and radiology services etc.

Geographical segments:

The Group operates in the business segment explained above in two principal geographical areas, India and outside India. The geographical segments have been identified as secondary segment. The Group operates in 2 main geographical segments, which contributes more than 10% of the Groups' revenue or segment assets. Outside India, Group now primarily operates in Dubai and Mauritius.



FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

Revenue from operations – by geographical segments

The following table shows the distribution of the Groups' consolidated revenues by geographical segment:

Region	Quarter ended	
	June 30, 2016	June 30, 2015
India	110,168	101,265
Outside India*	1,948	2,162
Total	112,116	103,427

(₹ in lacs)

* Includes revenue relating to discontinued operations (see note 8 below).

5. Other income includes interest income, foreign exchange fluctuation gain (net), profit on sale of assets (net), profit on sale (net)/ dividend on investments, forward cover premium amortization (net) and miscellaneous income, etc. whichever is relevant for the period.
6. In case of one of the subsidiary ("Escorts Heart Institute and Research Centre Limited") ("EHIRCL"), that was formed after amalgamation of Escorts Heart Institute and Research Centre ("EHIRC"), Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as a company:
 - a) Delhi Development Authority ("DDA") had terminated the lease deeds and allotment letters relating to land parcels on which hospital of EHIRCL exists. Consequent to termination, DDA issued show cause notice and initiated eviction proceedings against EHIRCL. Both these matters are currently pending in various courts of law. Based on the experts' opinions, management is confident that EHIRCL will be able to suitably defend the termination order and eviction proceedings and accordingly considers that no adjustments are required to the financial result.
 - b) Further, EHIRCL also has open tax demands of ₹ 7,181 lacs (after adjusting ₹ 3,590 lacs for which the Company has a legal right to claim from erstwhile promoters and ₹ 11,996 lacs of an escrow account which was maintained out of sale consideration payable by the Company to the erstwhile promoters) for various assessment years. During the year ended March 31, 2015, the Commissioner of Income Tax (Appeals) decided the case in favour of EHIRCL. Income Tax Department has filed an appeal before ITAT, which is yet to be fixed for hearing.
 - c) In relation to the order of the Honorable High Court of Delhi relating to provision of free treatment/ beds to poor, Directorate of Health Services ("DHS"), Government of NCT of Delhi, DHS appointed firm to calculate "unwarranted profits" arising to it due to non-compliance. During the year ended March 31, 2014, the Special Committee of DHS stated that before giving a formal hearing to the hospital, a formal intimation shall be given regarding the recoverable amount as per calculation of the appointed firm, which as per their method of calculations amounts to ₹ 73,266 lacs for the period 1984-85 to 2011-12, seeking hospital's comments and inputs, if any. The company responded to such intimation explaining errors and objections to the calculations. During the previous year, EHIRCL has received notice from DHS to appear for a formal and final hearing raising demand of recoverable amount to ₹ 50,336 lacs for the period till FY 2006-2007 in terms of above referred judgement, against which the Company has responded to such notice explaining errors and objections to the calculations. During the current quarter, DHS issued a demand notice dated June 9, 2016 directing EHIRCL to deposit INR 50,336 lacs within one month. EHIRCL challenged the demand notice by way of a writ petition in Delhi Hon'ble High Court on July 1, 2016. The Hon'ble High Court on its hearing of the matter on August 1, 2016, has disposed the petition of EHIRCL and has set aside the demand of INR 50,336 lacs which was raised vide notice dated June 9, 2016. DHS has now agreed to grant hearing to EHIRCL on the reply submitted to it. The hearing will be in accordance with the law. Based on its internal assessment and advice from its counsels on the basis of the documents available, management believes that it is in compliance of conditions of free treatment and free beds to the poor and does not anticipate liability after proper hearing with DHS.



FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

- 7 Exceptional gain/ (loss) included in the above consolidated financial results include:

Particulars	(₹ In lacs)	
	Quarter ended	
	June 30, 2016	June 30, 2015
a) Gain/(Loss) on sale of investment in Radlink Asia Pte Limited ("Radlink") [Refer note 8 (a)]	-	7,844
b) Gain on sale of investment in Fortis Healthcare Singapore Pte Limited ("FHS") [Refer note 8 (b)]	-	881
Net exceptional gain/ (loss)	-	8,725

8. a) Discontinued operations relating to Radlink-Asia Pte Limited, Singapore ("Radlink")

During the year ended March 31, 2015, Fortis Healthcare International Pte Limited (FHIPL), a wholly owned subsidiary of the Company announced its decision to divest its 100% shareholding in Radlink.

The transaction was completed on May 12, 2015 post approvals by the shareholders of Radlink and other regulatory authorities. The investment was sold to Fullerton Healthcare Group Pte. Limited for a consideration of SGD 111 million. Accordingly, assets and liabilities of Radlink do not form part of the consolidated assets and liabilities of the Company w.e.f. May 12, 2015. Such deconsolidation resulted in a net gain of ₹ 7,844 lacs and is included as an exceptional item in the quarter ended June 30, 2015.

The revenue and expenses in respect of the activities attributable to above discontinued operations included in the consolidated financial results are as follows:

Particulars	(₹ In lacs)	
	Quarter ended	
	June 30, 2016	June 30, 2015
Total income	-	1,062
Total expenses	-	934
Profit before tax	-	128
Tax expenses	-	27
Profit after tax	-	101

- b) Discontinued operations relating to Fortis Healthcare Singapore Pte Limited ("FHS")

During the year ended March 31, 2015, Fortis Healthcare International Pte Limited (FHIPL), a wholly owned subsidiary of the Company announced its decision to divest 100% shareholding in FHS which holds and operates Fortis Surgical Hospital to Concord Medical Services (International) Pte Limited for SGD 55 million.

The transaction was concluded on April 7, 2015. Accordingly, assets and liabilities of FHS do not form part of the consolidated assets and liabilities of the Company w.e.f. April 7, 2015. Such deconsolidation resulted in a net gain of ₹ 881 lacs and is included as an exceptional item in the quarter ended June 30, 2015.

The revenue and expenses in respect of the activities attributable to above discontinued operations included in the consolidated financial results are as follows:

Particulars	(₹ In lacs)	
	Quarter ended	
	June 30, 2016	June 30, 2015
Total income	-	-
Total expenses	-	-
Profit before tax	-	-
Tax expenses	-	-
Profit after tax	-	-




FORTIS HEALTHCARE LIMITED
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS


9. During the quarter ended June 30, 2015, as per the agreed issue terms, the Company redeemed on due date the outstanding USD 100 million 5% Foreign Currency Convertible Bonds (FCCBs) listed on the Luxembourg stock exchange.
10. The Group has elected to present earnings before interest, tax, depreciation and amortization (EBITDA) as a separate line item on the face of the statement of profit and loss. In its measurement, the Group includes other income, but does not include depreciation and amortization expense, finance costs, exceptional items, tax expenses and share in profit of associates and joint ventures.
11. The previous quarters' figures have been regrouped/ reclassified wherever necessary to correspond with the current quarters' classification/ disclosure.

Date: August 4, 2016
Place: Gurgaon



For and on behalf of the Board of Directors


Malvinder Mohan Singh
Executive Chairman



PRESS RELEASE

FORTIS INDIA OPERATIONS REPORTS ROBUST QUARTER; POSITIVE PAT

CONSOLIDATED INDIA REVENUES AT RS 1,102 CRS, UP 9%

EBITDAC AT RS 182 CRS, 16.5% MARGIN

BOARD PROVIDES AN IN-PRINCIPLE APPROVAL TO DEMERGE THE DIAGNOSTICS BUSINESS; TO MEET ON AUGUST 19, 2016 FOR FINAL APPROVAL

- **STRONG OPERATIONAL PERFORMANCE FROM THE HOSPITAL BUSINESS**
- **HOSPITAL BUSINESS REVENUES AT RS 910 CRS, UP 9%.**
- **HIGHEST EVER Q1 EBITDAC AT RS 139 CRS, 15.3% margin (14.4% in Q1 FY16)**
- **DIAGNOSTIC BUSINESS REVENUES AT RS 192 CRS, UP 7%, EBITDA AT RS 43 CRS, 22.4% MARGIN**

Gurgaon, August 4, 2016: Fortis Healthcare Ltd. (Fortis), India's leading healthcare delivery Company, today, announced its consolidated results for the quarter ended June 30, 2016 (Q1FY17).

The Board of Directors at its meeting held today, provided an in-principle approval to demerge the company's diagnostic business which includes operations of SRL Limited. The Board has formed a Restructuring Committee to detail the nuances of the demerger structure, including valuation, share entitlement ratio and other incidental matters and to present the same before the Board on August 19, 2016 for final approval.

India Business - Key Financial Highlights for the quarter (Q1FY17)

- Consolidated India Business Revenues at Rs 1,102 Cr, up 9%.
- Consolidated Operating EBITDAC for the India Business (EBITDA before net business trust costs) was at Rs 182 Cr, representing a margin of 16.5% versus 16.1% in the corresponding previous period.
- Consolidated Operating EBITDA for the India Business was at Rs 65 Cr, up 36%, representing a margin of 5.9% versus a margin of 4.7% in the corresponding previous period.
- PAT after minority interests and share in associates witnessed a significant improvement to Rs 15.1 Cr versus Rs (4.0) Cr in Q1FY16.



- Q1FY17 revenues for the India hospital business were at Rs 910 Cr, up 9% as compared to Q1FY16. Operating EBITDAC was at Rs 139 Cr, witnessing the highest ever EBITDAC for Q1 in a fiscal. The EBITDAC for the India hospital business represents a margin of 15.3%, up from 14.4% in Q1FY16. The EBITDA of the India hospital business has also witnessed a significant improvement, rising more than 4x as compared to the corresponding previous quarter.
- Key operational parameters in the Company's hospital business continued to see a healthy uptrend. The ARPOB (Average Revenue per Occupied Bed) grew to Rs 1.47 Cr compared to Rs 1.40 Cr in the corresponding previous quarter. ALOS (Average length of stay) was at 3.52 days versus 3.53 days while occupancy improved to 74% versus 70% in the corresponding previous quarter.
- FMRI, the Company's flagship facility recorded revenues of Rs 117 Cr in the quarter, a healthy growth of 21%. The facility continues to be the highest ARPOB generating hospital in the Company's network of multi-specialty hospitals with an ARPOB of Rs 2.72 Cr, an increase of 12% over the corresponding previous quarter. Revenue at Fortis Ludhiana, the other new facility, continued to ramp up. It recorded a revenue of Rs 27 Cr, an increase of 64% over the corresponding previous period.
- The India diagnostics business recorded revenues (net of inter company elimination) of Rs 192 Cr, up 7%. The operating EBITDA was at Rs 43 Cr, representing an EBITDA margin of 22.4% against 23.9% in Q1 FY16.

*EBITDAC refers to EBITDA before net business trust costs

Reported Group Financial Highlights for Q1FY17

The reported results for the quarter are not comparable with the corresponding previous period due to progressive divestments of the Company's international businesses.

- Consolidated Group Revenues for Q1FY17 were at Rs 1,121 Cr versus Rs 1,034 Cr for the previous quarter. Consolidated PAT after Minority Interest and share in associates (PATMI) for Q1FY17 was at Rs 16 Cr versus Rs 93 Cr in Q1FY16. The PATMI for the previous corresponding period includes a net exceptional gain of Rs 87 Cr as a result of the divestment of the international businesses in Singapore.



Commenting on the results, Mr Bhavdeep Singh, CEO, Fortis Healthcare Ltd, said, "At Fortis, our driving force and inspiration continues to be the vision of creating a world-class integrated healthcare delivery system combining the finest medical skills with patient-centric care and services. Driven by the values of Patient Centricity, Integrity, Innovation, Teamwork and Ownership, we are on the right track with hospital business up 9% and the highest ever Q1 EBITDAC at Rs 139 Cr. In the coming quarters, we will drive further substantive gains as we further accelerate our efforts across all focus areas."

The Company continued to maintain a healthy net debt to equity ratio at 0.18 times versus 0.13 times at the end of June 2015 and 0.16 times on March 31, 2016. Its net debt stood at Rs 873 Cr as of the quarter ended June 30, 2016.

Key Highlights Q1FY17 - Hospital Business

- During the quarter, the top 10 facilities contributed approx. 77% of the hospital business revenue. Most facilities, including the larger ones at FMRI, Shalimar Bagh, Noida, Anandapur, Mulund, and Ludhiana continued to exhibit growth momentum both in terms of revenues and operating margins.
- The contribution of International sales to the overall revenue of the Hospital business stood at 11 % (Rs 101 Cr), a robust growth of 21% over the the corresponding previous quarter.
- In order to further strengthen its clinical programs and have the best available talent for treating its patients, the Company during the quarter witnessed the joining of a number of senior consultants in the urology, nephrology and orthopaedics specialties. These eminent doctors would bring on board their immense knowledge and vast experience thus providing a sharper focus on enhancing patient care and clinical outcomes.
- The Company introduced and expanded its clinical programs and service offerings in several facilities in its network. These included:
 - Fortis La Femme, in collaboration with the Breat Milk Foundation launched the first pasteurized human milk bank "Amaara" in Delhi – NCR.
 - Fortis Escorts Hospital, Amritsar opened a multi-super specialty OPD center in Srinagar.
 - Fortis Escorts Jaipur witnessed the launch of the state of the art neuro navigation and neuro intervention technologies, further strengthening its neurology offerings.
 - Fortis Anandapur Kolkata launched the Heart Failure Clinic & Advanced Therapy Program in association with Fortis Malar, Chennai.
 - Fortis Malar Chennai launched a comprehensive colorectal clinic.

Key Highlights Q1FY17 - Diagnostics Business

- The lab medicine i.e. the pathology business contributed 85% to total revenues and grew 10% over the previous corresponding quarter. The contribution of the imaging business to total revenues declined to 7% from 10% in the corresponding previous period, mainly due to network rationalization. Clinical Trials, Wellness and the International segment contributed 7.5% to the overall revenues of the Diagnostics business.
- SRL performed over 3.78 million accessions during the quarter, a 6% growth over previous quarter. Through these accessions it undertook 8.6 million tests as compared to 8 million tests in Q1FY16.
- The business opened 20 new laboratories and exited 6. It added over 247 collection points and exited 101 while launching 7 new tests in the quarter. As of June 30, 2016, SRL had a network of 325 labs and approx. 7300 collection points.

Fortis dedicates 'Wall of Tribute' to salute organ donors

In a first-of-its-kind effort, Fortis has decided to keep alive the memory of organ donors and honour their families. The 'Wall of Tribute' being placed across various hospitals is part of Fortis Healthcare's national organ donation drive, '#MoreToGive'. The initiative salutes the families who had the courage to rise above their intense moments of grief and display tremendous magnanimity by donating the organs of their loved ones, saving many critical patients.

Awards & Accolades – Q1FY17

- Fortis Healthcare was adjudged "Hospital of the Year in India" and "Digital Savvy Hospital of the Year" at the 2016 APAC Healthcare and Medical Tourism Awards.
- Fortis Hospital, Anandapur, Kolkata; Fortis Hospital, BG Road, Bengaluru and Fortis Hospital, Mohali, received the coveted NABH Nursing Excellence Certification.
- Fortis Escorts Heart Institute, New Delhi; Fortis Hospital, Noida, and Fortis Hospital, Shalimar Bagh, received the "Green OT" certificate.
- Fortis Escorts Hospital, Jaipur, was applauded for its 'Excellence in Patient Care in the State of Rajasthan' at the 6th MT India Healthcare Awards.
- Fortis Hiranandani Hospital, Vashi, won four prestigious Golden Globe Tiger awards for the Best Quality Initiative in Healthcare, the Best Patient Safety Initiative in Healthcare, the Best Hospital in Paediatrics and Gynaecology, and the Best Green Hospital award.
- The Journal of the American Medical Association (JAMA), a publication respected by medical practitioners all over the world, published an original research conducted by Prof Upendra Kaul, Dean & Executive Director, Cardiology and Academics & Research Department, Fortis Escorts Heart Institute and Fortis Ft. Lt. Rajan Dhall Hospital, and his team. The study established that

Insulin requiring Diabetics do worse after Percutaneous Coronary Intervention (PCI) as compared to those who did not receive Insulin.

Some Cases of Clinical Excellence at Fortis – Q1FY17

- The Fortis Centre for Heart Failure & Transplant at Fortis Malar, Chennai, under the leadership of Dr K. R. Balakrishnan, Director, Cardiac Sciences and Dr Suresh Rao K. G., Head Cardiac Anaesthesia and Critical Care, created history by conducting the 100th successful heart transplant. The centre is one of the fastest in the country to have achieved the landmark. Meanwhile, Fortis Hospital, Mulund, conducted its 23rd heart transplant and Fortis Escorts Heart Institute, New Delhi, conducted its fourth.
- Extra Corporeal Cardiopulmonary Resuscitation (ECPR) was used to revive a 38-year-old man nearly 45 minutes after his heart had stopped beating, at Fortis Malar Hospital, Chennai.
- A 27-year-old Iraqi woman was treated at Fortis Memorial Research Institute (FMRI), Gurgaon, for a rare genetic condition that caused the duplication of several internal organs.
- A Coronary Artery Bypass Graft (CABG) surgery using total arterial grafts was performed on a 10-year-old boy suffering from a rare genetic disorder, Homozygous Familial Hypercholesterolemia (HoFH) at the Fortis Escorts Heart Institute (FEHI), New Delhi.
- A 7-year-old girl from Aligarh whose left hand was severed by a fodder cutting machine underwent a challenging and complex hand surgery at Fortis Hospital, Noida.
- An extremely complicated heart valve replacement surgery was performed on a 33-year-old patient from Nigeria at Fortis Hospital, Anandapur, Kolkata. Apart from a leaking heart valve, the patient suffered from sickle cell disease, a congenital blood disorder that made 89% of her red blood cells abnormal.
- An unusual case of 'simultaneous occlusions' or heart attacks in two different arteries of a 47-year-old fitness enthusiast and marathoner was treated at Fortis Hospital, Mulund, Mumbai.





About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and 325 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:

Ajeay Maharaj
Fortis Healthcare Ltd
9871798573

Anurag Kalra / Gaurav Chugh
Fortis Healthcare Ltd
9810109253 / 9958588900

